病毒血症
封锁
生物
病毒学
病毒
病毒复制
基因
基因表达
CCR5受体拮抗剂
抗体
免疫学
人类免疫缺陷病毒(HIV)
抗体反应
复制(统计)
期限(时间)
猿猴免疫缺陷病毒
下调和上调
基因表达调控
受体
病毒进入
候选基因
免疫系统
慢病毒
作者
Helen L. Wu,Gabriela M. Webb,Sebastian P. Fuchs,Cleiton T. Pessoa,Joseph M. Hwang,Hannah K Fisher,Allyson J. McCullen,Matthew C. Humkey,Mischa K Brown,Courtney M. Waytashek,Carla D. Boyle,Kaitlyn A. Kukula,Sofia K Potter,Garth W. Devlin,Zachary C. Elmore,Joshua A. Hull,Joanna Zikos,Tonya Swanson,Kimberly M. Armantrout,Kimberly Chun
标识
DOI:10.1126/scitranslmed.adw1976
摘要
Adeno-associated virus (AAV) vectors are promising vehicles for the delivery and long-term expression of antibodies for treatment of chronic diseases. Given the strong link between the C-C chemokine receptor 5 (CCR5)–Δ 32/ Δ 32 genotype and protection from HIV, we explored the ability of AAV vectors expressing the CCR5-blocking antibody leronlimab to mediate a functional cure in simian-human immunodeficiency virus (SHIV)–infected rhesus macaques by interrupting viral access to the viral entry co-receptor CCR5. Delivery of AAV-leronlimab to rhesus macaques elicited antidrug antibodies (ADA) and rapid plasma leronlimab clearance in approximately half of the treated macaques. However, in these same animals, we observed spontaneous leronlimab transgene reemergence and detectable CCR5 receptor occupancy approximately 1 year later that subsequently persisted indefinitely without rebound of ADA. In macaques that did not mount robust ADA responses, detectable plasma leronlimab concentrations and CCR5 receptor occupancy were maintained for more than 1 year. Of the nine macaques producing sufficient leronlimab to achieve full CCR5 receptor occupancy on blood CD4 + T cells, AAV-leronlimab drove stringent or partial control of SHIV viremia in six macaques long term. In the three macaques with uncontrolled SHIV viremia, short-term administration of exogenous leronlimab induced complete SHIV suppression in two and a 100-fold reduction in the third, indicating that a threshold of leronlimab expression is necessary to effectively halt SHIV replication. These results demonstrate the potential of gene therapy–mediated long-term antibody-based CCR5 blockade for HIV functional cure but highlight challenges in achieving sufficient antibody expression when targeting an abundant self-antigen.
科研通智能强力驱动
Strongly Powered by AbleSci AI